HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.
dc.contributor.author | Shirsat, Hemlata S | |
dc.contributor.author | Epari, Sridhar | |
dc.contributor.author | Shet, Tanuja | |
dc.contributor.author | Bagal, Rajani | |
dc.contributor.author | Hawaldar, Rohini | |
dc.contributor.author | Desai, Sangeeta B | |
dc.date.accessioned | 2012-10-17T04:29:53Z | |
dc.date.available | 2012-10-17T04:29:53Z | |
dc.date.issued | 2012-04 | |
dc.description.abstract | Introduction : HER2/neu gene status in breast cancers can be evaluated by targeting protein and gene - immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH). Recent studies have shown chromogenic in-situ hybridization (CISH) as a relatively cheaper alternative. Materials and Methods : Forty-three nonconsecutive, randomly selected primary invasive breast cancer cases were evaluated for c-erbB-2 (HER2 protein) by IHC and gene amplification by FISH and CISH. Results of each of the same were compared. Results : CISH showed approximately 90% and 100% concordance for IHC negative and positive cases, respectively; while approximately 94.4% and 91% concordance with FISH amplified and non-amplified cases, respectively. Conclusion : This study showed feasibility of incorporation of CISH as a low cost option in routine management of breast carcinoma in the Indian setting. Secondly, reconfirmation of IHC negative and positive cases can be done by CISH. | en_US |
dc.identifier.citation | Shirsat Hemlata S, Epari Sridhar, Shet Tanuja, Bagal Rajani, Hawaldar Rohini, Desai Sangeeta B. HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization. Indian Journal of Pathology & Microbiology. 2012 Apr-Jun 55(2): 175-179. | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/142216 | |
dc.language.iso | en | en_US |
dc.source.uri | https://www.ijpmonline.org/article.asp?issn=0377-4929;year=2012;volume=55;issue=2;spage=175;epage=179;aulast=Shirsat | en_US |
dc.subject | Breast cancer | en_US |
dc.subject | chromogenic in-situ hybridization | en_US |
dc.subject | fluorescence in-situ hybridization | en_US |
dc.subject | HER2/neu | en_US |
dc.subject | immunohistochemistry | en_US |
dc.subject.mesh | Breast Neoplasms --diagnosis | |
dc.subject.mesh | Breast Neoplasms --pathology | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Immunohistochemistry --economics | |
dc.subject.mesh | Immunohistochemistry --methods | |
dc.subject.mesh | In Situ Hybridization --economics | |
dc.subject.mesh | In Situ Hybridization --methods | |
dc.subject.mesh | India | |
dc.subject.mesh | Molecular Diagnostic Techniques --economics | |
dc.subject.mesh | Molecular Diagnostic Techniques --methods | |
dc.subject.mesh | Pathology --economics | |
dc.subject.mesh | Pathology --methods | |
dc.subject.mesh | Receptor, erbB-2 --biosynthesis | |
dc.title | HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization. | en_US |
dc.type | Article | en_US |